var data={"title":"Respiratory syncytial virus infection: Prevention","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Respiratory syncytial virus infection: Prevention</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/contributors\" class=\"contributor contributor_credentials\">Frederick E Barr, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/contributors\" class=\"contributor contributor_credentials\">Barney S Graham, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/contributors\" class=\"contributor contributor_credentials\">George B Mallory, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 30, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H104280778\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Respiratory syncytial virus (RSV) causes acute respiratory tract illness in persons of all ages. Almost all children are infected by two years of age, and reinfection is common [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/1\" class=\"abstract_t\">1</a>]. The clinical manifestations vary with age, health status, and whether the infection is primary or secondary.</p><p>The prevention of RSV infection will be discussed here. The epidemiology, microbiology, clinical manifestations, diagnosis, and treatment of RSV infection are discussed separately. (See <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-treatment\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2712293871\"><span class=\"h1\">TRANSMISSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Transmission of RSV is primarily by inoculation of nasopharyngeal or ocular mucous membranes after contact with virus-containing secretions or fomites. Direct contact is the most common route of transmission. The average duration of shedding is approximately 10 days. (See <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis#H10\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Clinical features and diagnosis&quot;, section on 'Microbiology'</a>.)</p><p class=\"headingAnchor\" id=\"H104278842\"><span class=\"h1\">GENERAL MEASURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prevention of RSV infection entails decreasing exposure to RSV and decreasing the risk of acquisition of infection <span class=\"nowrap\">and/or</span> development of disease if exposure occurs. Strategies to decrease exposure <span class=\"nowrap\">and/or</span> the risk of acquisition include [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,3\" class=\"abstract_t\">2,3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of exposure to tobacco and other smoke</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restricting participation in child care during RSV season for high-risk infants (if possible)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hand washing in all settings, particularly when high-risk infants are at risk for exposure to respiratory infections from older siblings [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/4,5\" class=\"abstract_t\">4,5</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Practicing cough hygiene</p><p/><p class=\"headingAnchor\" id=\"H104278849\"><span class=\"h1\">HEALTH CARE-ASSOCIATED INFECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>RSV is highly contagious and can cause serious health care-associated infections. The intensity of infection control precautions should be determined by the setting. Rapid diagnosis of RSV infection is essential for the institution of measures to prevent health care-associated infection for high-risk patients, including those with congenital heart or lung disease, bone marrow and lung transplant recipients, and the frail older adults with multiple underlying conditions.</p><p>Hand washing, and appropriate use of gloves are probably the most important infection control measures, but contact precautions, including surgical mask, eye protection, and disposable gowns for health care providers, should be used when there is a chance of exposure to aerosols of infectious respiratory secretions [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/6-14\" class=\"abstract_t\">6-14</a>]. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>.)</p><p>Isolation of patients in private rooms or in rooms with other RSV-infected patients (cohorting patients) and limited transport of patients from their rooms also are recommended [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/8,13,15\" class=\"abstract_t\">8,13,15</a>]. During outbreaks, personnel caring for RSV-infected patients should be restricted from caring for uninfected patients as often as possible. Immunoprophylaxis with <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> is not recommended for the prevention of health care-associated RSV [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Health care personnel should have continuing education about the symptoms, epidemiology, diagnosis, and transmission of RSV. Health care personnel and visitors with upper respiratory tract infections should be restricted from contact with high-risk patients as much as is practical, especially during the peak RSV transmission months [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/13,15,17\" class=\"abstract_t\">13,15,17</a>].</p><p class=\"headingAnchor\" id=\"H104278856\"><span class=\"h1\">IMMUNOPROPHYLAXIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunoprophylactic agents for RSV were developed after epidemiologic studies suggested that infants with high titers of maternally acquired RSV-neutralizing antibody develop less severe RSV disease, even though antibody does not prevent infection, and pilot studies indicated that monthly injections of intravenous immunoglobulin were safe and effective in decreasing the severity of subsequent RSV infections [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/18-20\" class=\"abstract_t\">18-20</a>].</p><p class=\"headingAnchor\" id=\"H104282122\"><span class=\"h2\">Immunoprophylactic agents</span></p><p class=\"headingAnchor\" id=\"H104278863\"><span class=\"h3\">Palivizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab</a> is a humanized monoclonal antibody against the RSV F glycoprotein (which is highly conserved among various isolates). It is licensed for the prevention of serious RSV lower respiratory tract disease in children at high risk of RSV disease [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/21\" class=\"abstract_t\">21</a>]. Palivizumab is easy to administer and does not interfere with response to routine immunization with live virus vaccines (eg, measles, mumps, rubella, varicella).</p><p class=\"headingAnchor\" id=\"H654989229\"><span class=\"h3\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>RSV <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (RSVIG), which is no longer available, was a polyclonal hyperimmune globulin prepared from donors with high serum titers of RSV neutralizing antibody. In controlled trials, RSVIG reduced RSV-associated hospitalizations among high-risk infants by 41 to 63 percent [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/22,23\" class=\"abstract_t\">22,23</a>]. However, its use was associated with increased morbidity and mortality in infants with congenital heart disease (CHD) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/23,24\" class=\"abstract_t\">23,24</a>]. In addition, as a blood product, RSVIG had the potential to interfere with the immune response to certain live virus vaccines (eg, measles, mumps, rubella, varicella) and to be contaminated with adventitious agents.</p><p>Motavizumab is another RSV-neutralizing monoclonal antibody that has undergone clinical trials for RSV prevention, but it is no longer available [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/25-27\" class=\"abstract_t\">25-27</a>].</p><p class=\"headingAnchor\" id=\"H104278870\"><span class=\"h2\">Indications for palivizumab</span></p><p class=\"headingAnchor\" id=\"H102717241\"><span class=\"h3\">Factors affecting decision</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Factors that influence the decision to administer <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> include [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,16,28\" class=\"abstract_t\">2,16,28</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The benefits of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> (eg, reduction in morbidity and mortality), which vary according to risk group (see <a href=\"#H104278870\" class=\"local\">'Indications for palivizumab'</a> above and <a href=\"#H100269015\" class=\"local\">'Other potential target groups'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hospitalization rates among children who do not receive prophylaxis (which may vary from country to country and clinician to clinician according to the threshold criteria for hospitalization) (see <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis#H2\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Clinical features and diagnosis&quot;, section on 'Epidemiology'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cost (which is affected by the number of doses administered and the weight of the infant)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Logistical difficulties of monthly administration (see <a href=\"#H104278877\" class=\"local\">'Dose and schedule'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The severity of the RSV season</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Distance to and availability of care for severe respiratory illness (see <a href=\"#H102717930\" class=\"local\">'Alaska Native/American Indian'</a> below)</p><p/><p>The efficacy of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> for preventing severe RSV infection in infants and children with prematurity, bronchopulmonary dysplasia (BPD), and CHD has been demonstrated in randomized controlled trials. A 2013 meta-analysis of three prelicensure randomized trials [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/29-31\" class=\"abstract_t\">29-31</a>] comparing palivizumab with placebo in 2831 high-risk infants (eg, preterm [&le;35 weeks gestation], BPD [also called chronic lung disease of prematurity], CHD) found that palivizumab reduced RSV hospitalizations from 101 to 50 per 1000 (relative risk [RR] 0.49 95% CI 0.37-0.64) and intensive care unit admissions from 34 to 17 per 1000 (RR 0.5 95% CI 0.3 to 0.81 in two studies with 2789 patients) without increasing the risk of adverse events [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/32\" class=\"abstract_t\">32</a>].</p><p>Postlicensure surveillance indicates the RSV-associated hospitalization rates among high-risk infants who receive <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> are similar to or lower than the RSV-associated hospitalization rates described above [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/33-39\" class=\"abstract_t\">33-39</a>]. However, in a cross-sectional analysis, all-cause hospitalization rates for bronchiolitis in children &lt;2 years in the United States declined by 17 percent between 2000 and 2009 (from 17.9 to 14.9 per 1000 person years) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/40\" class=\"abstract_t\">40</a>]. As the RSV hospitalization rate among children who do not receive palivizumab decreases, the number of patients who need to be treated to prevent one hospitalization increases, as does the cost-to-benefit ratio.</p><p>Studies of cost-effectiveness and cost-utility have inconsistent results and must be interpreted with caution [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/32\" class=\"abstract_t\">32</a>]. The technical review for the 2014 updated American Academy of Pediatrics (AAP) guidance for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis indicates that palivizumab &quot;cannot be considered as high-value health care for any group of infants&quot; because its high cost is associated with minimal benefit [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Professional groups, including the AAP [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>], the <a href=\"https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation&amp;token=jlh43geNbmYu2MCKYj86DoSJ0hAcw82F/J2YijfYIy29G0HE4c4Clonio7bBA2IJWfMZArkuLkjTVIpN41kgJ3mAlt2M8vZUIEH2YOQJgjM=&amp;TOPIC_ID=15389\" target=\"_blank\" class=\"external\">Joint Committee on Vaccination and Immunisation</a> of the United Kingdom Department of Health, and the <a href=\"http://www.cps.ca/en/documents&amp;token=f9c5FtURVFfftyf+WW/GbSkzigRq4QF4c4nkkhsFpny43dtS5ItgWCBJMVtVddXo&amp;TOPIC_ID=15389\" target=\"_blank\" class=\"external\">Canadian Paediatric Society</a>, have developed guidelines for prevention of RSV. Our recommendations are generally consistent with those of the 2014 AAP updated guidance for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,16\" class=\"abstract_t\">2,16</a>].</p><p class=\"headingAnchor\" id=\"H104282416\"><span class=\"h3\">Bronchopulmonary dysplasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis for infants younger than one year with BPD (ie, born at &lt;32 weeks gestation and required supplemental oxygen for the first 28 days after birth) and children younger than two years with BPD who required medical therapy (eg, supplemental oxygen, glucocorticoids, diuretics) for their pulmonary disease within six months of the anticipated RSV season [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>].</p><p>In subgroup analysis of a multicenter randomized trial that compared <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> and placebo in children with BPD or prematurity (&le;35 weeks gestation), palivizumab decreased the rate of hospitalization in 762 infants with BPD (7.9 versus 12.8 percent) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H104282430\"><span class=\"h3\">Prematurity without bronchopulmonary dysplasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommendations for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis among premature infants without BPD depend upon the degree of prematurity [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest that <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> be administered to preterm infants without BPD who were born at &le;28 weeks, 6 days of gestation and are younger than 12 months of age at the start of RSV season.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For preterm infants without BPD who were born between 29 and 32 weeks gestation, the authors of this topic review make decisions on a case-by-case basis after discussing the potential benefits and costs with the infant's caregiver(s). Additional factors to be considered in the decision include risk factors for severe disease (eg, young age [eg, &lt;4 months] during peak RSV season; older siblings in the home, who may be asymptomatic; prevalence of RSV in the community); and out-of-pocket costs [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/4,41-44\" class=\"abstract_t\">4,41-44</a>]. (See <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis#H8\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Clinical features and diagnosis&quot;, section on 'Risk factors'</a> and <a href=\"#H102717930\" class=\"local\">'Alaska Native/American Indian'</a> below.)</p><p/><p class=\"bulletIndent1\">Published studies do not provide a clear threshold of prematurity for which the benefits of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> are definitive [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/45\" class=\"abstract_t\">45</a>]. In subgroup analysis of a multicenter randomized trial that compared palivizumab and placebo in children with prematurity (&le;35 weeks gestation) or BPD, palivizumab decreased the rate of hospitalization in 740 infants with prematurity without BPD (1.8 versus 8.1 percent) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/30\" class=\"abstract_t\">30</a>]; further subgroup analysis according to gestational age was not performed. Several subsequent, population-based and cohort studies suggest that the risk of RSV hospitalization among infants born at &lt;29 weeks gestation is two to four times greater than in term infants, but the risk of RSV hospitalization among infants born at &ge;32 weeks gestation is similar to that in term infants [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/46-50\" class=\"abstract_t\">46-50</a>].</p><p/><p>In 2014, the AAP updated its guidance for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis in preterm infants. The AAP recommends against palivizumab prophylaxis for infants born at &ge;29 weeks gestation who have no additional risk factors for severe RSV disease [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>]. Previous guidance indicated that certain infants born at &ge;29 weeks gestation &quot;may benefit&quot; from palivizumab prophylaxis [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/51\" class=\"abstract_t\">51</a>].</p><p>Although <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> appears to reduce the risk of recurrent wheezing in premature infants without BPD or other underlying cardiopulmonary conditions [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/52-55\" class=\"abstract_t\">52-55</a>], palivizumab prophylaxis is not recommended to reduce the risk of recurrent wheezing or asthma in premature infants without BPD [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H100269015\"><span class=\"h3\">Other potential target groups</span></p><p class=\"headingAnchor\" id=\"H13838579\"><span class=\"h4\">Congenital heart disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Decisions regarding <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis for children with CHD should be individualized according to the degree of cardiovascular compromise (<a href=\"image.htm?imageKey=PEDS%2F73126\" class=\"graphic graphic_table graphicRef73126 \">table 1</a>) and made in consultation with the infant's cardiologist.</p><p><a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab</a> prophylaxis is more likely to be beneficial for infants &le;12 months of age who have [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acyanotic heart disease and are receiving medication to control heart failure and will require cardiac surgical procedures</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate to severe pulmonary hypertension</p><p/><p>Infants with CHD who are receiving <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis and require cardiac bypass during RSV season should receive a postoperative dose of palivizumab 15 <span class=\"nowrap\">mg/kg</span> intramuscularly (IM) as soon as they are medically stable because the mean serum palivizumab concentration has been observed to decrease by more than 50 percent after cardiac bypass [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16,29,56\" class=\"abstract_t\">16,29,56</a>].</p><p>The benefits of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> for children with hemodynamically significant CHD were demonstrated in a multicenter randomized trial that included 1287 children younger than two years [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/29\" class=\"abstract_t\">29</a>]. Palivizumab reduced laboratory confirmed RSV hospitalization (5.3 versus 9.7 percent; 45 percent reduction, 95% CI 23-67) and duration of hospitalization (57.4 versus 129.0 days per 100 children). In subgroup analysis, palivizumab reduced RSV hospitalization among children with acyanotic heart disease (5.0 versus 11.8 percent) and cyanotic heart disease (5.6 versus 7.9 percent), but the reduction in children with cyanotic heart disease was not statistically significant (p = 0.29).</p><p>Subsequent observational studies suggest that the rate of RSV hospitalization for children with hemodynamically significant CHD who do not receive <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> is only 2 to 3 percent [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/57-60\" class=\"abstract_t\">57-60</a>], which is lower than in the placebo recipients in the randomized trial (9.7 percent) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/29\" class=\"abstract_t\">29</a>]. As the RSV hospitalization among children with hemodynamically significant CHD who do not receive palivizumab decreases, the number of patients who need to be treated to prevent one hospitalization increases, as does the cost-to-benefit ratio.</p><p>The 2014 AAP guidance for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis indicates that clinicians &quot;may administer&quot; palivizumab prophylaxis to certain infants with hemodynamically significant heart disease during the first year of life [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H13838531\"><span class=\"h4\">Neuromuscular disorder</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Decisions regarding <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis during the first year of life for children with neuromuscular disease that impairs the ability to clear secretions from the upper airway (eg, ineffective cough) should be made on a case-by-case basis. Such children may be at risk for prolonged hospitalization related to lower respiratory tract infections. However, population-based and prospective studies defining the risk of RSV hospitalization in children with neuromuscular disease are lacking [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,16\" class=\"abstract_t\">2,16</a>].</p><p class=\"headingAnchor\" id=\"H13838538\"><span class=\"h4\">Pulmonary abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Decisions regarding <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis during the first year of life for children with pulmonary malformations, tracheoesophageal fistula, upper airway conditions, or conditions requiring tracheostomy should be made on a case-by-case basis. Children with these conditions may be at risk for prolonged hospitalization related to lower respiratory tract infection. However, population-based and prospective studies defining the risk of RSV hospitalization in children with pulmonary abnormalities are lacking [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,16\" class=\"abstract_t\">2,16</a>].</p><p class=\"headingAnchor\" id=\"H92967269\"><span class=\"h4\">Cystic fibrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not suggest <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis for children with cystic fibrosis (CF) unless they have other indications for palivizumab. Although RSV appears to be associated with pulmonary exacerbation in children with CF [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/61\" class=\"abstract_t\">61</a>], the benefits of palivizumab have not been well studied.</p><p>A 2016 systematic review identified one randomized trial of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis in children with CF and concluded that additional randomized trials are necessary to draw firm conclusions about the safety and efficacy of palivizumab in children with CF [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/62\" class=\"abstract_t\">62</a>]. (See <a href=\"topic.htm?path=cystic-fibrosis-overview-of-the-treatment-of-lung-disease#H22\" class=\"medical medical_review\">&quot;Cystic fibrosis: Overview of the treatment of lung disease&quot;, section on 'Palivizumab'</a>.)</p><p>The 2014 AAP guidance for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis indicates that palivizumab may be warranted for children &lt;12 months with CF and evidence of chronic lung disease <span class=\"nowrap\">and/or</span> nutritional compromise and children &lt;2 years with CF and manifestations of severe lung disease (ie, previous hospitalization for pulmonary exacerbation, abnormalities on chest radiography or chest tomography that persist when stable, or weight for length &lt;10<sup>th</sup> percentile) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H104282503\"><span class=\"h4\">Immunocompromised host</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Decisions regarding <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis in immunocompromised hosts must be made on a case-by-case basis. Although palivizumab prophylaxis has not been evaluated in immunocompromised children in controlled trials, children with severe immunodeficiencies (eg, severe combined immunodeficiency or severe acquired immunodeficiency, children younger than two years who have undergone lung transplantation or hematopoietic stem cell transplantation) may benefit from immunoprophylaxis [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,16\" class=\"abstract_t\">2,16</a>].</p><p class=\"headingAnchor\" id=\"H100269022\"><span class=\"h4\">Down syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prophylactic <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> may be warranted for infants with Down syndrome and additional risk factors for RSV lower respiratory tract infection, including birth during the peak of RSV season.</p><p>Down syndrome, independent of prematurity or hemodynamically significant CHD, appears to be a risk factor for RSV lower respiratory tract infection and hospitalization [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/63-68\" class=\"abstract_t\">63-68</a>]. RSV immunoprophylaxis has not been evaluated in children with Down syndrome in controlled trials. However, in a prospective cohort study, administration of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> was associated with decreased risk of hospitalization among children &lt;2 years of age with Down syndrome [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/69\" class=\"abstract_t\">69</a>]. Confirmation of this finding in a randomized trial is necessary before palivizumab can be routinely recommended for children with Down syndrome.</p><p class=\"headingAnchor\" id=\"H102717930\"><span class=\"h4\">Alaska Native/American Indian</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A lower threshold for administration of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis may be warranted for Alaska Native and American Indian infants &lt;12 months of age because of the higher rates of RSV hospitalization and the costs associated with transport of such infants from remote locations [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2,16,70-74\" class=\"abstract_t\">2,16,70-74</a>]. In a placebo-controlled randomized trial, motavizumab (another humanized monoclonal antibody) reduced the risk of RSV hospitalization in Native American infants who were younger than six months and born at &ge;36 weeks gestation (2 versus 11 percent, RR 0.13, 95% CI 0.08-0.21) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H104278877\"><span class=\"h2\">Dose and schedule</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dose of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> is 15 <span class=\"nowrap\">mg/kg</span> IM once per month for a maximum of five doses, with a maximum interval between doses of 35 days. The first dose is administered before the RSV season begins (usually in November in the northern hemisphere, but may vary by geographic region) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Infants who qualify for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> but remain hospitalized when the first dose is due may receive the first dose 48 to 72 hours before discharge home or promptly after discharge. The timing of the first dose may depend upon whether or not the infant's insurance provides coverage for inpatient administration. Palivizumab is not recommended for prevention of health care-associated RSV during the birth hospitalization. (See <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis#H3\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Clinical features and diagnosis&quot;, section on 'Seasonality'</a> and <a href=\"#H104278849\" class=\"local\">'Health care-associated infection'</a> above.)</p><p>In the United States, when an infant qualifies for initiation of prophylaxis at the beginning of the RSV season, it is recommended that all five doses should be administered, even if the infant becomes old enough that prophylaxis is no longer indicated [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>]. As an example, an infant born at &lt;29 weeks who is without BPD or CHD and turns 12 months old in January should still receive immunoprophylaxis in February and March. Fewer than five doses may be administered to an infant who qualifies for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> and is born during the RSV season [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"abstract_t\">16</a>]. As a general rule, an infant born in February would receive only two doses (February and March) but may receive more if the local RSV season extends into April or May. The hospital laboratory or health department may have data to help determine when the local RSV season has ended.</p><p>Other countries may use abbreviated schedules of three or four doses, but studies evaluating the effectiveness of abbreviated or partial schedules in preventing RSV hospitalization have conflicting results [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/75,76\" class=\"abstract_t\">75,76</a>].</p><p>Data from the <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab</a> Outcomes Registry, including nearly 20,000 infants who received palivizumab between 2000 and 2004, indicate that approximately 80 percent of palivizumab recipients received all five doses and between 65 and 70 percent of palivizumab recipients received the second through fifth doses within 35 days of the previous dose [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/33\" class=\"abstract_t\">33</a>]. No association was detected between receiving all five doses and RSV hospitalization. However, infants who received the second through fifth doses of palivizumab within 35 days of the previous dose had a lower risk of hospitalization than those who did not (odds ratio [OR] 0.7, 95% CI 0.54 to 0.91). In another observational study of Medicaid claims data (2003 to 2009), receiving the first dose of palivizumab after November 30 or gaps of &gt;35 days between consecutive doses also was associated with increased risk of RSV-related hospitalization (11.7 versus 7.9 percent; OR 1.21, 95% CI 1.09-1.34) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/76\" class=\"abstract_t\">76</a>].</p><p class=\"headingAnchor\" id=\"H92967376\"><span class=\"h3\">Breakthrough RSV infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunoprophylaxis should be discontinued if the infant experiences breakthrough infection requiring hospitalization. The risk of a second RSV hospitalization during the same season is extremely low (&lt;0.5 percent) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/26,77\" class=\"abstract_t\">26,77</a>]. In addition, repeat infections generally are less severe than the initial infection.</p><p class=\"headingAnchor\" id=\"H104278884\"><span class=\"h2\">Home administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Administration of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> in the home setting may increase adherence to the schedule [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/33,78-80\" class=\"abstract_t\">33,78-80</a>]. Administration in the home setting was associated with a decreased rate of RSV-associated hospitalization in the 2000 to 2004 Palivizumab Outcomes Registry (0.4 versus 1.2 percent when administered in the outpatient setting) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/80\" class=\"abstract_t\">80</a>].</p><p class=\"headingAnchor\" id=\"H104278898\"><span class=\"h2\">Adverse events</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rare cases of severe hypersensitivity reactions have been described after an initial dose, as well as after reexposure [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/34,81\" class=\"abstract_t\">34,81</a>]. Among 13,025 infants enrolled in the Canadian registry of children receiving <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> for RSV (2008 to 2013), six patients (0.05 percent) had 14 hypersensitivity reactions (2.8 per 10,000 patient-months) [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/81\" class=\"abstract_t\">81</a>]. Only four other patients had serious adverse events that were possibly or probably related to palivizumab, but the events could not be classified because the records were incomplete.</p><p>In two studies evaluating the safety of <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> during two consecutive seasons, no serious adverse events were noted [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/82,83\" class=\"abstract_t\">82,83</a>]. Only 1 of 118 children had a significant increase in antipalivizumab antibody titer, and the antibody response declined with continued dosing [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/82,83\" class=\"abstract_t\">82,83</a>]. In a 2014 systematic review, escape mutants resistant to palivizumab were isolated from approximately 5 percent of children who were receiving monthly palivizumab prophylaxis and required hospitalization for breakthrough RSV infection [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2\" class=\"abstract_t\">2</a>].</p><p><a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab</a> does not interfere with routine childhood immunizations.</p><p class=\"headingAnchor\" id=\"H104278905\"><span class=\"h1\">VACCINE DEVELOPMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are multiple challenges to the development of a successful RSV vaccine. Immature immunity and possible suppression of an immune response by maternal antibody are issues in the target population of young infants [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/84\" class=\"abstract_t\">84</a>]. The vaccine must be protective against antigenically divergent strains. In addition, it must not potentiate disease in recipients who subsequently become infected with wild-type virus, as occurred in trials with a formalin-inactivated vaccine developed in the 1960s [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/85-89\" class=\"abstract_t\">85-89</a>].</p><p>Live attenuated RSV vaccines are being developed and tested. Although several biologically attenuated candidate vaccines have induced an antibody response in young infants, they have been insufficiently attenuated for use in this age group [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/90\" class=\"abstract_t\">90</a>]. Recombination technology was used to produce an attenuated strain that was well tolerated by one- to two-month-old infants in one report [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/91\" class=\"abstract_t\">91</a>]. However, only 44 percent of subjects had a detectable antibody response. A newer approach that increases transcription while restricting replication resulted in significantly higher neutralizing activity and is being evaluated for efficacy [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/92\" class=\"abstract_t\">92</a>].</p><p>Subunit vaccines have been developed from RSV fusion (F) and G glycoproteins. Historically, trials conducted in adults, older adults, pregnant women, and children &ge;12 months of age have been successful in demonstrating some rise in antibody titers but have not significantly increased neutralizing activity or reduced clinical disease [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/93,94\" class=\"abstract_t\">93,94</a>]. However, advances in understanding the crystal structure of the prefusion RSV F glycoprotein conformation have led to identification of a new class of glycoprotein F specific antibodies that are at least 100 times more potent than <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/95,96\" class=\"abstract_t\">95,96</a>]. Subunit candidate RSV vaccines based on the stabilized prefusion F are in early clinical development, and new prefusion F-specific monoclonal antibodies are in advanced clinical evaluation [<a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/97\" class=\"abstract_t\">97</a>].</p><p>A variety of gene-based vaccine vectors, nucleic acid vaccines, particle-based approaches, and novel adjuvants for candidate RSV vaccines are also in preclinical and early phase clinical development.</p><p class=\"headingAnchor\" id=\"H2931696294\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-bronchiolitis-in-infants-and-children\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Bronchiolitis in infants and children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topic (see <a href=\"topic.htm?path=bronchiolitis-and-rsv-in-infants-and-children-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H104280568\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of respiratory syncytial virus (RSV) infection entails decreasing exposure to RSV and decreasing the risk of acquisition of infection <span class=\"nowrap\">and/or</span> the development of severe disease if exposure occurs. General strategies for prevention include avoidance of tobacco and other smoke, restricting participation in child care during RSV season for high-risk infants (if possible), hand washing, and practicing cough hygiene. (See <a href=\"#H104278842\" class=\"local\">'General measures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measures for the prevention of health care-associated RSV infections include handwashing and appropriate use of gloves and contact precautions (including masks and eye protection) for health care workers. <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab</a> prophylaxis is not recommended for the prevention of health care-associated RSV infection. (See <a href=\"#H104278849\" class=\"local\">'Health care-associated infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis for (<a href=\"grade.htm?i=4\" class=\"grade\">Grade 2A</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Infants younger than one year with bronchopulmonary dysplasia (BPD) (ie, who were born at &lt;32 weeks gestation and required supplemental oxygen for the first 28 days after birth) and infants younger than two years with BPD who required medical therapy (eg, supplemental oxygen, glucocorticoids, diuretics) within six months of the anticipated RSV season. (See <a href=\"#H104282416\" class=\"local\">'Bronchopulmonary dysplasia'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Infants younger than one year who were born at &lt;29 weeks (ie, &le;28 weeks, 6 days) of gestation. For infants younger than one year who were born between 29 and 32 weeks of gestation, the authors of this topic review individualize decisions about <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a>. (See <a href=\"#H104282430\" class=\"local\">'Prematurity without bronchopulmonary dysplasia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other potential target groups for <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis may include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Infants younger than one year of age with hemodynamically significant congenital heart disease (<a href=\"image.htm?imageKey=PEDS%2F73126\" class=\"graphic graphic_table graphicRef73126 \">table 1</a>) (see <a href=\"#H13838579\" class=\"local\">'Congenital heart disease'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Children younger than one year of age with neuromuscular disorders that impair the ability to clear secretions from the upper airways or pulmonary abnormalities (see <a href=\"#H13838531\" class=\"local\">'Neuromuscular disorder'</a> above and <a href=\"#H13838538\" class=\"local\">'Pulmonary abnormalities'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Children younger than two years of age who will be profoundly immunocompromised (eg, those with severe combined immunodeficiency, those younger than two years of age who have undergone lung transplantation or hematopoietic stem cell transplantation) during the RSV season (see <a href=\"#H104282503\" class=\"local\">'Immunocompromised host'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Children with Down syndrome who have additional risk factors for RSV lower respiratory tract infection (see <a href=\"#H100269022\" class=\"local\">'Down syndrome'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Alaska Native and American Indian infants (see <a href=\"#H102717930\" class=\"local\">'Alaska Native/American Indian'</a> above)</p><p/><p class=\"bulletIndent1\">Decisions regarding <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> prophylaxis for children in these groups should be made on a case-by-case basis. (See <a href=\"#H100269015\" class=\"local\">'Other potential target groups'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab</a> 15 <span class=\"nowrap\">mg/kg</span> is administered intramuscularly once per month for a maximum of five doses. The first dose is administered before the RSV season begins (usually in November for infants in the northern hemisphere). When palivizumab prophylaxis is initiated at the beginning of RSV season, all five doses should be administered. However, prophylaxis should be discontinued if the infant experiences breakthrough infection requiring hospitalization. (See <a href=\"#H104278877\" class=\"local\">'Dose and schedule'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serious adverse events (eg, severe hypersensitivity reaction) associated with <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">palivizumab</a> administration are rare. Palivizumab-resistant isolates have been recovered from approximately 5 percent of children hospitalized with breakthrough RSV infection while receiving monthly palivizumab prophylaxis. (See <a href=\"#H104278898\" class=\"local\">'Adverse events'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/1\" class=\"nounderline abstract_t\">Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/2\" class=\"nounderline abstract_t\">American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:e620.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/3\" class=\"nounderline abstract_t\">Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134:e1474.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/4\" class=\"nounderline abstract_t\">Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis 2014; 209:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/5\" class=\"nounderline abstract_t\">Hall CB, Geiman JM, Biggar R, et al. Respiratory syncytial virus infections within families. N Engl J Med 1976; 294:414.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/6\" class=\"nounderline abstract_t\">Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child 1981; 135:512.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/7\" class=\"nounderline abstract_t\">Murphy D, Todd JK, Chao RK, et al. The use of gowns and masks to control respiratory illness in pediatric hospital personnel. J Pediatr 1981; 99:746.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/8\" class=\"nounderline abstract_t\">Krasinski K, LaCouture R, Holzman RS, et al. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission. J Pediatr 1990; 116:894.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/9\" class=\"nounderline abstract_t\">Agah R, Cherry JD, Garakian AJ, Chapin M. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Routine isolation procedure vs routine procedure supplemented by use of masks and goggles. Am J Dis Child 1987; 141:695.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/10\" class=\"nounderline abstract_t\">Gala CL, Hall CB, Schnabel KC, et al. The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection. JAMA 1986; 256:2706.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/11\" class=\"nounderline abstract_t\">Leclair JM, Freeman J, Sullivan BF, et al. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med 1987; 317:329.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/12\" class=\"nounderline abstract_t\">Thorburn K, Kerr S, Taylor N, van Saene HK. RSV outbreak in a paediatric intensive care unit. J Hosp Infect 2004; 57:194.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/13\" class=\"nounderline abstract_t\">Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53:1.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/14\" class=\"nounderline abstract_t\">Harris JA, Huskins WC, Langley JM, et al. Health care epidemiology perspective on the October 2006 recommendations of the Subcommittee on Diagnosis and Management of Bronchiolitis. Pediatrics 2007; 120:890.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/15\" class=\"nounderline abstract_t\">Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) 1989; 68:269.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/16\" class=\"nounderline abstract_t\">American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415.</a></li><li class=\"breakAll\">Welliver RC, Hall CB. Respiratory syncytial virus. In: Feigin and Cherry&rsquo;s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison G, Kaplan SL, et al (Eds), Elsevier, Philadelphia 2018. p.1780.</li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/18\" class=\"nounderline abstract_t\">Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/19\" class=\"nounderline abstract_t\">Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993; 37:1655.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/20\" class=\"nounderline abstract_t\">Groothuis JR, Levin MJ, Rodriguez W, et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother 1991; 35:1469.</a></li><li class=\"breakAll\">Synagis (palivizumab) injection. US Food &amp; Drug Administration (FDA) approved product inforamtion. Revised March, 2014.  US National Library of Medicine. Available online at www.dailymed.nlm.nih.gov (Accessed on July 28, 2014).</li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/22\" class=\"nounderline abstract_t\">Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997; 99:93.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/23\" class=\"nounderline abstract_t\">Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329:1524.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/24\" class=\"nounderline abstract_t\">Simoes EA, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998; 133:492.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/25\" class=\"nounderline abstract_t\">Carbonell-Estrany X, Sim&otilde;es EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:e35.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/26\" class=\"nounderline abstract_t\">Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70:186.</a></li><li class=\"breakAll\">AstraZeneca discontinues development of motavizumab for RSV prophylaxis indication www.astrazeneca.com/Media/Press-releases/Article/AstraZeneca-discontinues-motavizumab-RSV (Accessed on May 22, 2013).</li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/28\" class=\"nounderline abstract_t\">Meissner HC, Kimberlin DW. RSV immunoprophylaxis: does the benefit justify the cost? Pediatrics 2013; 132:915.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/29\" class=\"nounderline abstract_t\">Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/30\" class=\"nounderline abstract_t\">Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/31\" class=\"nounderline abstract_t\">Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:110.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/32\" class=\"nounderline abstract_t\">Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013; :CD006602.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/33\" class=\"nounderline abstract_t\">Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28:511.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/34\" class=\"nounderline abstract_t\">Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/35\" class=\"nounderline abstract_t\">Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000; 19:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/36\" class=\"nounderline abstract_t\">Oh PI, Lanct&ocirc;t KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002; 21:512.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/37\" class=\"nounderline abstract_t\">Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a &quot;real life&quot; experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006; 41:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/38\" class=\"nounderline abstract_t\">Medrano L&oacute;pez C, Garc&iacute;a-Guereta L, CIVIC Study Group. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J 2010; 29:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/39\" class=\"nounderline abstract_t\">Mitchell I, Paes BA, Li A, et al. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 2011; 30:651.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/40\" class=\"nounderline abstract_t\">Hasegawa K, Tsugawa Y, Brown DF, et al. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics 2013; 132:28.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/41\" class=\"nounderline abstract_t\">Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137:865.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/42\" class=\"nounderline abstract_t\">Houben ML, Bont L, Wilbrink B, et al. Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics 2011; 127:35.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/43\" class=\"nounderline abstract_t\">Munywoki PK, Koech DC, Agoti CN, et al. Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household Cohort. J Infect Dis 2015; 212:1711.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/44\" class=\"nounderline abstract_t\">Haerskjold A, Kristensen K, Kamper-J&oslash;rgensen M, et al. Risk Factors for Hospitalization for Respiratory Syncytial Virus Infection: A Population-based Cohort Study of Danish Children. Pediatr Infect Dis J 2016; 35:61.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/45\" class=\"nounderline abstract_t\">Pignotti MS, Carmela Leo M, Pugi A, et al. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol 2016; 51:1088.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/46\" class=\"nounderline abstract_t\">Winterstein AG, Knox CA, Kubilis P, Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr 2013; 167:1118.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/47\" class=\"nounderline abstract_t\">Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013; 132:e341.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/48\" class=\"nounderline abstract_t\">Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154:55.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/49\" class=\"nounderline abstract_t\">Gijtenbeek RG, Kerstjens JM, Reijneveld SA, et al. RSV infection among children born moderately preterm in a community-based cohort. Eur J Pediatr 2015; 174:435.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/50\" class=\"nounderline abstract_t\">Sheridan-Pereira M, Murphy J, Sloan J, et al. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study. Pediatr Infect Dis J 2016; 35:19.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Respiratory syncytial virus. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.609.</li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/52\" class=\"nounderline abstract_t\">Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368:1791.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/53\" class=\"nounderline abstract_t\">Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151:34.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/54\" class=\"nounderline abstract_t\">Yoshihara S, Kusuda S, Mochizuki H, et al. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics 2013; 132:811.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/55\" class=\"nounderline abstract_t\">Mochizuki H, Kusuda S, Okada K, et al. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. Am J Respir Crit Care Med 2017; 196:29.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/56\" class=\"nounderline abstract_t\">Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13:420.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/57\" class=\"nounderline abstract_t\">Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114:1606.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/58\" class=\"nounderline abstract_t\">Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs. Acta Paediatr 2006; 95:404.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/59\" class=\"nounderline abstract_t\">Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, et al. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004; 89:961.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/60\" class=\"nounderline abstract_t\">Li A, Wang DY, Lanct&ocirc;t KL, et al. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). Pediatr Infect Dis J 2017; 36:445.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/61\" class=\"nounderline abstract_t\">Somayaji R, Goss CH, Khan U, et al. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study. Clin Infect Dis 2017; 64:1760.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/62\" class=\"nounderline abstract_t\">Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2016; 7:CD007743.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/63\" class=\"nounderline abstract_t\">Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. Pediatrics 2007; 120:e1076.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/64\" class=\"nounderline abstract_t\">Zachariah P, Ruttenber M, Sim&otilde;es EA. Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr 2012; 160:827.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/65\" class=\"nounderline abstract_t\">Kristensen K, Hjuler T, Ravn H, et al. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 2012; 54:810.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/66\" class=\"nounderline abstract_t\">Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009; 94:785.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/67\" class=\"nounderline abstract_t\">Stagliano DR, Nylund CM, Eide MB, Eberly MD. Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr 2015; 166:703.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/68\" class=\"nounderline abstract_t\">Galleguillos C, Galleguillos B, Larios G, et al. Down's syndrome is a risk factor for severe lower respiratory tract infection due to respiratory syncytial virus. Acta Paediatr 2016; 105:e531.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/69\" class=\"nounderline abstract_t\">Yi H, Lanct&ocirc;t KL, Bont L, et al. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics 2014; 133:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/70\" class=\"nounderline abstract_t\">Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002; 110:e20.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/71\" class=\"nounderline abstract_t\">Lowther SA, Shay DK, Holman RC, et al. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J 2000; 19:11.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/72\" class=\"nounderline abstract_t\">Bruden DJ, Singleton R, Hawk CS, et al. Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children. Pediatr Infect Dis J 2015; 34:945.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/73\" class=\"nounderline abstract_t\">O'Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 2015; 15:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/74\" class=\"nounderline abstract_t\">Banerji A, Ng K, Moraes TJ, et al. Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic. CMAJ Open 2016; 4:E623.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/75\" class=\"nounderline abstract_t\">Lavoie PM, Solimano A, Taylor R, et al. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab. JAMA Pediatr 2016; 170:174.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/76\" class=\"nounderline abstract_t\">Krilov LR, Masaquel AS, Weiner LB, et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr 2014; 14:261.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/77\" class=\"nounderline abstract_t\">Yamaguchi M, Sano Y, Dapat IC, et al. High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan. J Clin Microbiol 2011; 49:1034.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/78\" class=\"nounderline abstract_t\">Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004; 23:318.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/79\" class=\"nounderline abstract_t\">Hand IL, Noble L, Geiss D, Shotkin A. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J 2008; 27:175.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/80\" class=\"nounderline abstract_t\">Frogel M, Nerwen C, Boron M, et al. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Infect Dis J 2008; 27:870.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/81\" class=\"nounderline abstract_t\">Chen JJ, Chan P, Paes B, et al. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS One 2015; 10:e0134711.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/82\" class=\"nounderline abstract_t\">Null D Jr, Pollara B, Dennehy PH, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005; 24:1021.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/83\" class=\"nounderline abstract_t\">Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003; 26:283.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/84\" class=\"nounderline abstract_t\">Nyiro JU, Kombe IK, Sande CJ, et al. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya. PLoS One 2017; 12:e0177803.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/85\" class=\"nounderline abstract_t\">Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/86\" class=\"nounderline abstract_t\">Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/87\" class=\"nounderline abstract_t\">Graham BS, Henderson GS, Tang YW, et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/88\" class=\"nounderline abstract_t\">Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988; 26:1595.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/89\" class=\"nounderline abstract_t\">Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196:859.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/90\" class=\"nounderline abstract_t\">Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/91\" class=\"nounderline abstract_t\">Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/92\" class=\"nounderline abstract_t\">Karron RA, Luongo C, Thumar B, et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med 2015; 7:312ra175.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/93\" class=\"nounderline abstract_t\">Polack FP, Karron RA. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 2004; 23:S65.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/94\" class=\"nounderline abstract_t\">Falloon J, Yu J, Esser MT, et al. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. J Infect Dis 2017; 216:1362.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/95\" class=\"nounderline abstract_t\">McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013; 340:1113.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/96\" class=\"nounderline abstract_t\">McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592.</a></li><li><a href=\"https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-prevention/abstract/97\" class=\"nounderline abstract_t\">Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017; 9.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15389 Version 31.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H104280568\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H104280778\" id=\"outline-link-H104280778\">INTRODUCTION</a></li><li><a href=\"#H2712293871\" id=\"outline-link-H2712293871\">TRANSMISSION</a></li><li><a href=\"#H104278842\" id=\"outline-link-H104278842\">GENERAL MEASURES</a></li><li><a href=\"#H104278849\" id=\"outline-link-H104278849\">HEALTH CARE-ASSOCIATED INFECTION</a></li><li><a href=\"#H104278856\" id=\"outline-link-H104278856\">IMMUNOPROPHYLAXIS</a><ul><li><a href=\"#H104282122\" id=\"outline-link-H104282122\">Immunoprophylactic agents</a><ul><li><a href=\"#H104278863\" id=\"outline-link-H104278863\">- Palivizumab</a></li><li><a href=\"#H654989229\" id=\"outline-link-H654989229\">- Other agents</a></li></ul></li><li><a href=\"#H104278870\" id=\"outline-link-H104278870\">Indications for palivizumab</a><ul><li><a href=\"#H102717241\" id=\"outline-link-H102717241\">- Factors affecting decision</a></li><li><a href=\"#H104282416\" id=\"outline-link-H104282416\">- Bronchopulmonary dysplasia</a></li><li><a href=\"#H104282430\" id=\"outline-link-H104282430\">- Prematurity without bronchopulmonary dysplasia</a></li><li><a href=\"#H100269015\" id=\"outline-link-H100269015\">- Other potential target groups</a><ul><li><a href=\"#H13838579\" id=\"outline-link-H13838579\">Congenital heart disease</a></li><li><a href=\"#H13838531\" id=\"outline-link-H13838531\">Neuromuscular disorder</a></li><li><a href=\"#H13838538\" id=\"outline-link-H13838538\">Pulmonary abnormalities</a></li><li><a href=\"#H92967269\" id=\"outline-link-H92967269\">Cystic fibrosis</a></li><li><a href=\"#H104282503\" id=\"outline-link-H104282503\">Immunocompromised host</a></li><li><a href=\"#H100269022\" id=\"outline-link-H100269022\">Down syndrome</a></li><li><a href=\"#H102717930\" id=\"outline-link-H102717930\">Alaska Native/American Indian</a></li></ul></li></ul></li><li><a href=\"#H104278877\" id=\"outline-link-H104278877\">Dose and schedule</a><ul><li><a href=\"#H92967376\" id=\"outline-link-H92967376\">- Breakthrough RSV infection</a></li></ul></li><li><a href=\"#H104278884\" id=\"outline-link-H104278884\">Home administration</a></li><li><a href=\"#H104278898\" id=\"outline-link-H104278898\">Adverse events</a></li></ul></li><li><a href=\"#H104278905\" id=\"outline-link-H104278905\">VACCINE DEVELOPMENT</a></li><li><a href=\"#H2931696294\" id=\"outline-link-H2931696294\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H104278912\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H104280568\" id=\"outline-link-H104280568\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/15389|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/73126\" class=\"graphic graphic_table\">- RSV prophylaxis and CHD</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-overview-of-the-treatment-of-lung-disease\" class=\"medical medical_review\">Cystic fibrosis: Overview of the treatment of lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bronchiolitis-and-rsv-in-infants-and-children-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Respiratory syncytial virus infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-syncytial-virus-infection-treatment\" class=\"medical medical_review\">Respiratory syncytial virus infection: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-bronchiolitis-in-infants-and-children\" class=\"medical medical_society_guidelines\">Society guideline links: Bronchiolitis in infants and children</a></li></ul></div></div>","javascript":null}